Roxbury Financial LLC Invests $126,000 in Natera, Inc. (NASDAQ:NTRA)

Roxbury Financial LLC purchased a new stake in Natera, Inc. (NASDAQ:NTRA) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 753 shares of the medical research company’s stock, valued at approximately $126,000.

Several other institutional investors have also modified their holdings of NTRA. Blue Trust Inc. boosted its stake in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares during the period. Versant Capital Management Inc raised its position in Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after acquiring an additional 166 shares during the last quarter. Covestor Ltd lifted its stake in Natera by 34.3% in the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares in the last quarter. True Wealth Design LLC purchased a new position in Natera in the 3rd quarter valued at about $57,000. Finally, Brooklyn Investment Group purchased a new stake in Natera in the 3rd quarter worth approximately $70,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Stock Up 1.6 %

NASDAQ:NTRA opened at $173.39 on Friday. The firm’s fifty day moving average price is $167.75 and its two-hundred day moving average price is $142.83. Natera, Inc. has a one year low of $68.03 and a one year high of $183.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm’s quarterly revenue was up 63.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.95) EPS. On average, analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have commented on NTRA. Guggenheim boosted their price objective on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Piper Sandler boosted their target price on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th. TD Cowen increased their target price on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, Canaccord Genuity Group upped their price target on Natera from $165.00 to $180.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. One investment analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and a consensus target price of $165.88.

Insider Buying and Selling at Natera

In related news, insider John Fesko sold 663 shares of the business’s stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the sale, the insider now directly owns 156,044 shares of the company’s stock, valued at $27,739,941.88. The trade was a 0.42 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Michael Burkes Brophy sold 43,502 shares of Natera stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $176.88, for a total value of $7,694,633.76. Following the transaction, the chief financial officer now owns 70,629 shares of the company’s stock, valued at $12,492,857.52. This trade represents a 38.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 305,454 shares of company stock worth $51,290,625 over the last 90 days. Insiders own 7.60% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.